In the SURMOUNT trial program, mean weight reduction on tirzepatide reached roughly 15 to 21% of body weight at 72 weeks across the studied maintenance doses, and about 20% against semaglutide's 14% in the only head-to-head trial. On a 250 lb starting weight that is roughly 38 to 53 lb; on 180 lb, roughly 27 to 38 lb.
Those are trial means under trial conditions. Real-world averages run lower, principally because a large share of patients discontinue inside the first year. Read the numbers below as what good conditions produce, not as a forecast.
| Starting weight | 5% | 10% | 15% | 20% | 22.5% |
|---|---|---|---|---|---|
| 180 lb | 9 lb → 171 lb | 18 lb → 162 lb | 27 lb → 153 lb | 36 lb → 144 lb | 40 lb → 140 lb |
| 200 lb | 10 lb → 190 lb | 20 lb → 180 lb | 30 lb → 170 lb | 40 lb → 160 lb | 45 lb → 155 lb |
| 220 lb | 11 lb → 209 lb | 22 lb → 198 lb | 33 lb → 187 lb | 44 lb → 176 lb | 50 lb → 170 lb |
| 250 lb | 12 lb → 238 lb | 25 lb → 225 lb | 38 lb → 212 lb | 50 lb → 200 lb | 56 lb → 194 lb |
| 280 lb | 14 lb → 266 lb | 28 lb → 252 lb | 42 lb → 238 lb | 56 lb → 224 lb | 63 lb → 217 lb |
| 320 lb | 16 lb → 304 lb | 32 lb → 288 lb | 48 lb → 272 lb | 64 lb → 256 lb | 72 lb → 248 lb |
| 350 lb | 18 lb → 332 lb | 35 lb → 315 lb | 52 lb → 298 lb | 70 lb → 280 lb | 79 lb → 271 lb |
Why percentages rather than pounds
Trials report percentage of body weight because it is the only figure that compares across participants. A 40 lb loss is a different achievement at 350 lb than at 180 lb, and an average expressed in pounds would be dominated by whoever happened to be heaviest. When a program advertises “lose up to 50 lb,” it is quoting an outcome available only to people starting heavy enough for it.
What each band actually buys clinically
A sustained 5% reduction improves blood pressure, glycaemic markers and triglycerides measurably. Around 10% starts to move sleep apnea severity and fatty liver. Around 15% is where the trial programs begin reporting meaningful shifts in cardiometabolic risk. Beyond that the returns continue but flatten, which is why a patient content at 12% has not failed at anything.
The cost of a percentage point
Dividing a first-year cost by the weight it is likely to remove gives a blunt but clarifying figure. At the cheapest tracked route ($2,388 for a first year), a 250 lb patient reaching each band pays roughly:
| Reduction | From 200 lb | From 250 lb | Cost per lb at 250 lb |
|---|---|---|---|
| 5% of body weight | 10 lb from 200 lb | 12 lb from 250 lb | $191 |
| 10% of body weight | 20 lb from 200 lb | 25 lb from 250 lb | $96 |
| 15% of body weight | 30 lb from 200 lb | 38 lb from 250 lb | $64 |
| 20% of body weight | 40 lb from 200 lb | 50 lb from 250 lb | $48 |
| 22.5% of body weight | 45 lb from 200 lb | 56 lb from 250 lb | $42 |
What moves you up a band
Four things, in order of effect. Reaching and holding an adequate maintenance dose rather than stalling mid-titration. Not interrupting therapy, since time on treatment predicts outcome more strongly than anything else available to you. Protein intake sufficient to protect lean mass, because a share of any weight lost on an energy deficit is muscle and lost muscle lowers resting energy expenditure. And resistance training two to three times weekly through the course rather than after it.
What the table cannot tell you
Where you personally will land. Response varies widely around every mean above, roughly a tenth of trial participants were low responders, and mean reduction in patients with type 2 diabetes runs consistently below that in patients without it. A clinician with your history is the only source of a personal estimate.
What Tirzepatide Weight Loss Looks Like at Your Starting Weight: the shortest useful summary
Tirzepatide is a once-weekly injection titrated from 2.5 mg to a 15 mg ceiling in 2.5 mg steps at intervals of at least four weeks, producing roughly 15 to 21% mean weight reduction across the studied maintenance arms at 72 weeks and about 20% against semaglutide's 14% in the only head-to-head trial. It works while it is taken; the withdrawal evidence shows substantial regain after stopping. Compounded preparations cost from $133 a month and are not FDA-approved; brand product is approved and costs considerably more.
Those five facts decide most questions people arrive with. Everything else on this page is detail underneath them — which is worth reading before you spend $2,388 on a first year, but not worth confusing with the outline.
What Tirzepatide Weight Loss Looks Like at Your Starting Weight: where to go next
If you have not chosen a program, price your expected maintenance dose with the projector rather than reading advertisements. If you have, check what it charges at 10 mg against the price-by-dose table. If you are struggling with side effects, the side-effect reference covers each one with reported frequencies and the red flags that need a clinician. And if a program has refused to name its pharmacy, the verification walkthrough explains why that single answer outranks any price difference.
People also ask about tirzepatide weight loss by starting weight
What is tirzepatide weight loss by starting weight?
Tirzepatide weight loss by starting weight is covered in full on this page, with the clinical detail drawn from the tirzepatide prescribing information and the published SURMOUNT and SURPASS trial program, and any price figures drawn from our tracked dataset and dated to their last verification.
Does tirzepatide weight loss by starting weight apply to compounded tirzepatide as well as Zepbound?
The molecule is the same, so the clinical content applies to both. What differs is regulatory status, dose metering and price: compounded preparations are not FDA-approved, arrive as a multi-dose vial you measure yourself, and cost a fraction of the brand routes.
How much does tirzepatide weight loss by starting weight cost per month in 2026?
Compounded tirzepatide runs from $133 per month at the entry dose across the 21 compounded programs we track. At a 10 mg maintenance dose the cheapest tracked route is Oak Longevity at $199 per month, or about $2,388 for a first year on the standard escalation. Brand Zepbound through manufacturer self-pay sits well above that and pharmacy retail well above again. Verified 2026-08-05.
Is tirzepatide weight loss by starting weight FDA-approved?
Brand tirzepatide (Zepbound and Mounjaro) is FDA-approved. Compounded tirzepatide is not: FDA does not approve compounded drugs and does not review them for safety, effectiveness or quality before they are marketed. The active molecule is the same; the regulatory review is not.
Sources
- US prescribing information for tirzepatide (Zepbound and Mounjaro), Eli Lilly and Company.
- SURMOUNT-1 — tirzepatide once weekly for the treatment of obesity, NCT04184622.
- SURMOUNT-5 — tirzepatide versus semaglutide in adults with obesity, NCT05822830.
- US Food and Drug Administration, human drug compounding — compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality before marketing.
- Program pricing as recorded in our open dataset, with a verification date on every record.